The therapeutic community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to offer a more substantial dec